Progress in Medicinal Chemistry Volume 39
-
- Hardcover ausgewählt
- Taschenbuch
- eBook
-
Sprache:Englisch
-
Verlag:Elsevier Science & Technology
- Elsevier Science Fr. 222.00
- Elsevier LTD Fr. 202.00
- Elsevier Science Bv Fr. 72.90
- Elsevier LTD, Oxford Fr. 228.00
- Elsevier Science & Technology Fr. 208.00
- Elsevier Science & Technology Fr. 208.00
- Elsevier Science & Technology Fr. 212.00 ausgewählt
- Elsevier Science & Technology Fr. 212.00
- Elsevier Science & Technology Fr. 212.00
- Elsevier Science & Technology Fr. 219.00
- Elsevier Science & Technology Fr. 228.00
- Elsevier Science & Technology Fr. 228.00
- Elsevier Science & Technology Fr. 228.00
- Elsevier Science & Technology Fr. 228.00
- Elsevier Science & Technology Fr. 228.00
- Elsevier Science & Technology Fr. 229.00
- Elsevier Science & Technology Fr. 229.00
- Elsevier Bv Fr. 197.00
- Elsevier Bv Fr. 221.00
- Elsevier Bv Fr. 221.00
Fr. 212.00
inkl. gesetzl. MwSt.,
Beschreibung
Produktdetails
Einband
Gebundene Ausgabe
Erscheinungsdatum
24.04.2002
Herausgeber
F. D. King + weitereVerlag
Elsevier Science & TechnologySeitenzahl
273
Maße (L/B/H)
21.4/14.8/1.7 cm
Gewicht
520 g
Sprache
Englisch
ISBN
978-0-444-50959-8
This volume covers contemporary advances in five important areas of pharmacology and medicinal chemistry including: a comprehensive account of inhibitors of the caspase family of proteolytic enzymes that represent a new class of anti-inflammatory and antiapoptotic agents of potential value in rheumatoid arthritis, and other peripheral and central indications; adoc umented survey of semi-synthetic and totally synthetic antibiotics and anti HIV agents and their sites of interaction; inhibitors of the intracellular enzyme acyl-CoA: cholesterol O-acyltransferase (ACAT) developed for the treatment of hypercholesterolemia; and recent progress in growth hormone secretagogues, with the focus on strategies to improve oral bioavailability and duration of action. Inhibition of the proteolytic enzyme, hepatitis C protease N-3(NS3), required for viral replication, is one of the most attractive targets for HCV infections. Progress and prospects in the design of peptide and non-peptide inhibitors are described here. design and clinical potential of new drug molecules; valuable summaries of structure-activity relationships in topical areas of medicinal chemistry; and extensive references to the biology, medicinal chemistry and clinical aspects of each topic.
Noch keine Bewertungen vorhanden
Verfassen Sie die erste Bewertung zu diesem Artikel
Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.